GSA Capital Partners’s 2seventy bio TSVT Stock Holding History

GSA Capital Partners’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-62,269	Closed	-$308K	–	2158
2025 Q1	$308K	Sell	62,269 -51,804	-45%	-$165K	0.03%	1134
2024 Q4	$335K	Buy	114,073 +100,594	+746%	+$413K	0.02%	1147
2024 Q3	$64K	Buy	+13,479	New	+$60.8K	﹤0.01%	1512
2023 Q1	–	Sell	-10,186	Closed	-$95K	–	1942
2022 Q4	$95K	Buy	+10,186	New	+$144K	0.01%	1314
2022 Q2	–	Sell	-10,740	Closed	-$183K	–	1805
2022 Q1	$183K	Buy	+10,740	New	+$182K	0.02%	1194

Other funds holding TSVT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GSA Capital Partners's TSVT Position: Q2 2025 in Review

GSA Capital Partners sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 62,269 shares — an estimated $308K sold.

GSA Capital Partners first reported a position in TSVT in Q1 2022 and held it in 5 quarters. The position peaked at $335K in Q4 2024. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

GSA Capital Partners reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 62,269 2seventy bio shares in Q2 2025, an estimated $308K.
GSA Capital Partners first reported a position in 2seventy bio in Q1 2022 and held it in 5 quarters.
GSA Capital Partners's 2seventy bio position peaked at $335K in Q4 2024.
2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.